HCV News Week Ending 02/01/2015

HCV News

Week Ending 02/01/2015

Pregnant Women With Hep C Have 6% Chance of Passing Virus to Baby

'Pregnant women with hepatitis C virus (HCV) have an estimated 5.8 percent risk of transmitting the virus to their unborn child, a risk that more than doubles if they are coinfected with HIV. Publishing their findings in Clinical Infectious Diseases, researchers conducted a meta-analysis of 109 studies to make their estimates about the risk of mother-to-child transmission (MTCT).'

Interferon-free regimen well tolerated in HIV/HCV coinfected patients

'Treatment with an interferon-free regimen of sofosbuvir and ribavirin was well tolerated in patients with HIV/HCV coinfection and yielded improvements in patient-reported outcome scores that were comparable to those achieved by patients with HCV monoinfection, according to recent findings.'

PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

'Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus.'

ADAP Crisis Task Force Announces Groundbreaking Agreement with AbbVie for Hepatitis C Treatment Viekira Pak ™

'The ADAP Crisis Task Force (Task Force) has reached a new pricing agreement between AbbVie and AIDS Drug Assistance Programs (ADAPs) for Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) for the treatment of hepatitis C (HCV). AbbVie is the first company to offer a discount on the ADAP price of an HCV medication in the era of new curative HCV treatments.'

Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent

'Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C.'

Egypt has highest infection level of hepatitis C: study

'Up to 5,000 new hepatitis C virus (HCV) infections occur in Egypt annually as a result of mother-to-child transmission, according to a new study by researchers from Weill Cornell Medical College in Qatar (WCMC-Q) and London School of Hygiene and Tropical Medicine in the UK.'
Caring Ambassadors Program Inc.
Jill Wolf, LCSW

Comments are closed.